NVAX - Novavax Corp Year-over-year net earnings per share growth for the last 12 months

Corporate emblem and logo of Novavax (NVAX)

Novavax, Inc. (NVAX) experiences unstable cash flows dependent on government contracts, yet its status as a defensive asset during recessions ensures an inflow of funds. Quarterly EPS variation illustrates this balance, and 84.60 becomes the new value for this metric. Profit dynamics are subject to strong autumn seasonality and regulatory risks, rendering the final financial results volatile.

Novavax (NVAX) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/15/2026
Manufactured product of novavax.com

For Novavax, Inc. (NVAX), quarterly EPS growth serves as an indicator of the actual efficiency of earnings per share generation. The quarterly EPS growth trajectory on GURU.Markets reflects the percentage change in net income, adjusted for one-time factors. This metric measures the recovery rate of business profitability. For the vaccine manufacturer, this is a critical marker of the ability to overcome liquidity shortages and production disruptions. The trend of this indicator determines the company's viability in competition with pharma behemoths.

Competitor analysis

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CVAC|Quarterly EPS earnings growth valneva.com|Year-over-year net earnings per share growth for the last 12 months VIR (Vir Biotechnology)|Year-over-year net earnings per share change for the last twelve months SIGA Technologies Inc|Year-over-year earnings per share growth for the last twelve months Emergent Bio EBS|Quarterly EPS earnings growth Atea Pharmaceuticals AVIR|IVVD - Year-over-year earnings per share growth for the last twelve months|ENTA (Enanta Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|INO (Inovio) - Year-over-year net earnings per share growth for the last 12 months|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)